HARMONY BIOSCIENCES HOLDINGS, INC.

HRMY ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $158.7M $145.5M $128.9M $181.5M $34.6M $-36.9M $-152.0M
Depreciation & Amortization
Depreciation $267.0K $514.0K $419.0K $416.0K $394.0K $395.0K
Amortization $23.8M $23.8M $23.8M $23.0M $18.4M $9.8M $2.8M
Stock-Based Compensation $44.9M $42.6M $31.7M $26.2M $15.7M $4.7M $9.9M
Net Cash from Operating Activities $348.2M $219.8M $219.4M $144.5M $98.6M $-3.0M $-75.4M
Investing Activities
Capital Expenditures $310.0K $1.2M $312.0K $172.0K $298.0K $2.0K $149.0K
Business Acquisitions $37.0M
Net Cash from Investing Activities $-39.6M $-67.5M $-46.4M $-141.8M $-100.3M $-2.0M $-127.1M
Financing Activities
Dividends Paid
Stock Repurchases $100.0M $167.0K
Net Cash from Financing Activities $-9.0M $-11.0M $-105.6M $6.8M $7.4M $209.2M $143.8M
Net Change in Cash $299.5M $141.3M $67.4M $9.5M $5.7M $204.2M $-58.8M
Free Cash Flow $347.9M $218.7M $219.1M $144.3M $98.3M $-3.0M $-75.6M